Healthcare
One of the most defining developments in contemporary healthcare is the transition from activity-based to value-based delivery. Currently, many healthcare providers are remunerated based on their level of activity, which encourages focus on activities rather than improvements in patient health and life quality. The introduction of value-based payment schemes, which reward better patient outcomes, is an essential part in creating the healthcare providers of tomorrow, where patients’ quality of life is the main objective.
The introduction of value-based healthcare will have a variety of implications for healthcare providers, payers, patients and the life sciences industry. One implication will be a change towards much more individualized patient care than the predominantly standardized treatment packages of today, especially for the growing number of chronically ill patients in need of long-term care. Continued development towards value-based healthcare will reveal further implications, which may disrupt current business models, as well as creating new possibilities.
Life Sciences
The life sciences industry is an increasingly important part of many national economies and plays a vital role in creating research-based economic growth. In order to uphold or grow strong clusters, governments and industry leaders are turning to national strategies for their life sciences clusters. These strategies shed light on solutions to challenges regarding attraction and retention of companies and skilled personnel. The conditions offered to perform R&D, and in particular clinical research, are central criteria when assessing the attractiveness of a jurisdiction.
Our Healthcare & Life Sciences team helps clients adapt to new regulatory landscapes such as the ongoing transition from activity-based to value-based healthcare delivery and to stay attractive in the global competition for life sciences industry.
We design, analyse, and test value-based healthcare models customised for specific disease areas. This includes identifying consequences and implications by introducing value-based healthcare models for various stakeholders, such as the effect on payments, financial compensation and patient outcomes in terms of health and life quality.
We design and evaluate new regulatory models and their effects on GDP, employment, and public finances. This includes studies on consequences of public sector revisions of legislation for certain patient groups. Our clients apply the results directly in their dialogue with stakeholders such as ministries and the general public.
We assist clients with strategies for building stronger life sciences clusters. Any life sciences cluster needs to be attractive to companies as well as to skilled personnel. State-of-the-art clusters must be so on a global scale. This requires high standards in a number of areas such as education, entrepreneurship and R&D. Our work includes studies on the attractiveness of jurisdictions and initiatives for improvements.
